1 To characterize the prostanoid receptors (TP, FP, EP 1 and/or EP 3 ) involved in the vasoconstriction of human pulmonary veins, isolated venous preparations were challenged with dierent prostanoid-receptor agonists in the absence or presence of selective antagonists. 2 The stable thromboxane A 2 mimetic, U46619, was a potent constrictor agonist on human pulmonary veins (pEC 50 =8.60+0.11 and E max =4.61+0.46 g; n=15). The anity values for two selective TP-antagonists (BAY u3405 and GR32191B) versus U46619 were BAY u3405: pA 2 =8.94+0.23 (n=3) and GR32191B: apparent pK B =8.25+0.34 (n=3), respectively. These results are consistent with the involvement of TP-receptor in the U46619 induced contractions.
Introduction
Prostanoids may contract or relax smooth muscle by activating dierent prostanoid receptors (Coleman et al., 1994) . Results derived from isolated tissues showed that prostanoid activation of TP-, FP-, EP 1 -or EP 3 -receptors produced smooth muscle contraction by increasing Ca 2+ or reducing cyclic AMP intracellular levels (Negishi et al., 1995) . The preferential receptor for thromboxane A 2 (TPreceptor) has been extensively described in platelet aggregation and in smooth muscle contraction (Shen & Tai, 1998) . In most of the human arteries, U46619 the TP selective agonist induced contraction (Maddox et al., 1985; Ohlstein et al., 1988; Uski et al., 1984; Baxter et al., 1995; Templeton et al., 1991) , while studies on human veins have been rarely reported. However, the TP-receptor has been described in vasoconstriction of veins in the hand, the placenta and the leg Boura et al., 1986; Mais et al., 1985) . The involvement of FP-, EP 1 -or EP 3 -receptors in the contraction of numerous non-human smooth muscle preparations is frequently reported. The activation of FP-receptors by prostanoids induced contraction of cat iris sphincter, bovine ciliary muscle, rabbit uterus and ewe myometrium (Woodward et al., 1989; Krauss et al., 1997; Chen et al., 1998; Crankshaw & Gaspar, 1995) . In mammals, activation of EP 3 -receptor induced contraction of smooth muscles present in ileum, colon, myometrium and corpus luteum (Botella et al., 1993; 1995; Crankshaw & Gaspar, 1995; Sharif et al., 1998) . The EP 1 -receptor has been classically described using selective antagonist (SC19220) against PGE 2 -induced contractions in preparations derived from either the guinea-pig trachea or gastrointestinal tract (Kennedy et al., 1982; Coleman & Kennedy, 1985) . However, few studies characterizing FP-, EP 1 -or EP 3 -receptors involved in the control of human vascular tone have been reported. The FP-receptor has been described in dierent non-vascular human smooth muscle: urinary bladder, and myometrium (Palea et al., 1998; Senior et al., 1992) . Furthermore, EP 1 -receptors have not been associated with any human smooth muscle contraction and there is limited data on human pulmonary artery and myometrium contractions due to EP 3 -receptor activation (Qian et al., 1994; Senior et al., 1993) .
The aim of the present study was to investigate not only the TP but also the FP-, EP 1 -or EP 3 -receptors associated with the contractions induced by prostanoids in human pulmonary veins.
Methods

Isolated preparations
Human lung tissues were obtained from patients (21 male and four female) who had undergone surgery for lung carcinoma. The mean age was 58+2 years. Pulmonary venous preparations were removed, dissected free from adjoining connective tissue and lung parenchyma, placed in Tyrode's solution (concentration mM): NaCl 139.2, KCl 2.7, CaCl 2 1.8, MgCl 2 0.49, NaHCO 3 11.9, NaH 2 PO 4 0.4 and glucose 5.5; pH 7.4 and maintained at 48C. All preparations were used within 1 ± 12 h postsurgery. Vascular preparations with intact endothelium were cut as rings (3 ± 6 mm internal diameter, 3 ± 5 mm in length). The rings were then set up in 10 ml organ baths containing Tyrode's solution, gassed with 95% O 2 /5% CO 2 and maintained at 378C. An optimal load (1.5 g), which ensured maximal physiological responses to the agonists, was applied to each ring.
Changes in force were recorded by isometric force displacement transducers (Narco F-60) and physiographs (Linseis). Subsequently, preparations were allowed to equilibrate for 90 min with bath¯uid changes taking place every 10 min.
Experimental protocol
After the equilibration period, the venous preparations were incubated 30 min with indomethacin (1.7 mM) and 15 min with N G -nitro-L-arginine (L-NOARG; 0.1 mM). These agents were used to avoid any physiological eect induced by the release of endogenous prostanoids and nitric oxide. The preparations were then contracted with increasing concentrations of prostanoids or selective agonists applied in a cumulative fashion. In some experiments, during the incubation period, dierent antagonists: BAY u3405 (TP), GR32191B (TP), AH6809 (DP/EP 1 /EP 2 ) or SC19220 (EP 1 ) were added with indomethacin and L-NOARG. These antagonist were used to determine either their anity values or to illustrate one response through activation of a single receptor subtype for the agonists which may act on dierent receptor subtypes. The maximal contraction of each preparation with norepinephrine (10 mM) was obtained at the end of each experimental protocol.
Data analysis
The changes in force were measured from isometric recordings in grams (g). The contractions produced with the dierent agonists were expressed either as grams or as per cent of the contraction induced with norepinephrine. The maximal contraction (E max value) produced with an agonist and the half-maximum eective concentration value (EC 50 value) were interpolated from the individual concentrationeect curves. The pEC 50 values were calculated as the negative log of EC 50 values. When the pEC 50 values obtained in the absence and presence of antagonist were signi®cantly dierent and the tentative assumption was made that the Schild equation held in our experiments, then the apparent pK B value was calculated as the negative log of the equilibrium dissociation constant for the antagonist (K B value). The K B value was determined using the Schild equation: K B =[B]/(DR-1), where [B] is the concentration of the antagonist and DR (dose ratio) is the ratio of EC 50 values of agonist in the presence and absence of antagonist. In studies on veins with the contractile agonist U46619, dierent concentrations of BAY u3405 were used to determine the pA 2 value according to the method of Arunlakshana & Schild (1959) . For each lung sample, Schild plot analysis was performed, the slope and pA 2 value were determined by least square ®tting of a regression line to the points. All results are expressed as means+s.e.mean and were derived from dierent lung samples (n). Statistical analysis was performed using Student's paired or unpaired t-test and Mann-Whitney rank sum test with a con®dence level of 95%.
Compounds U46619 (9,11-dideoxy-11a,9a-methanoepoxy PGF 2a ), PGE 2 , PGF 2a ,¯uprostenol ((+) 16-m-tri¯uoromethylphenoxy tetranor PGF 2a ) and 17-phenyl-trinor-PGE 2 , were purchased from Cayman Chemical Company, Ann Arbor, MI, 
Results
The cocktail of inhibitors (indomethacin, L-NOARG) and antagonists with which the venous preparations were incubated induced a small contraction on the resting tone of these preparations (0.07+0.06 g; n=18). At the end of the protocols, venous preparations were contracted with norepinephrine (10 mM: 3.10+0.44 g; n=25).
Concentration-dependent contractions of human pulmonary venous preparations produced by U46619 are shown Figure 1a and Table 1 . U46619 was a potent constrictor with a maximal eect which was 50% greater than that induced by norepinephrine (10 mM). BAY u3405 (0.03; 0.1; 0.3 mM) caused a concentration-related rightward shift of the U46619 concentration-eect curves with a pA 2 of 8.94+0.23 (n=3) and a Schild plot slope of 1.07+0.03, which was not signi®cantly dierent from unity. These values were derived from Schild plots (Figure 1b ). In additional lung samples, BAY u3405 and GR32191B (1 mM) reduced the E max and/or the pEC 50 values obtained from U46619 concentration-eect curves (Table 1) . In presence of BAY u3405 (1 mM) the U46619 concentration-eect curves were dicult to restore and no plateau was reached even at the maximal concentration available for U46619 (10 mM). When possible, the apparent pK B values for each concentration of BAY u3405 and GR32191B were calculated and these values are presented Table 1 .
Concentration-eect curves induced by sulprostone on human pulmonary venous preparations in the absence of antagonist were biphasic, the average curve failed to reach a plateau and was not sigmoõÈ dal ( Figure 2) . The contraction obtained with the highest available concentration of sulprostone was 54+09% (n=5) of norepinephrine contraction ( Figure 2 ). SigmoõÈ dal curves were obtained with sulprostone, in the presence of either BAY u3405 (1; 10 mM) or GR32191B (10 mM) and the E max did not exceed 50% of the norepinephrine contraction ( Figure 2 and Table  1 ).
In presence of BAY u3405 (1 mM), the contractions induced by sulprostone on venous preparations were inhibited by AH6809 (10; 30 or 100 mM; Figure 3a and Table 1 ). AH6809 (30, 100 mM) had a non-competitive behaviour on sulprostone responses, the antagonism was not reversible. Under the same conditions (presence of BAY u3405, 1 mM), SC19220 (100 mM) signi®cantly inhibited the vasoconstrictions induced by sulprostone ( Figure 3a ). In presence of this latter treatment, the contraction obtained with the highest available concentration of sulprostone was 32+09% (n=3) of norepinephrine contraction, the derived estimations of pEC 50 and apparent pK B were (56.97+0.41, 44.75+0.36), respectively. AH6809 (10 mM) signi®cantly inhibited the vasoconstrictions induced by 17-phenyl-PGE 2 in the human pulmonary veins treated with BAY u3405, 1 mM, (Figure 3b and Table 1 ). In this latter protocol, the contraction obtained with the highest available concentration of 17-phenyl-PGE 2 was 15+05% (n=4) of norepinephrine contraction and the derived estimations of pEC 50 and the apparent pK B were (57.66+0.13, 45.88+0.20), respectively. Venous preparations derived from three human lung samples, treated with BAY u3405 (1 mM), contracted when challenged with iloprost ( Figure 4 ) this response was abolished in the presence of AH6809 (10 mM). In the presence of BAY u3405 (1 mM), the PGE 2 concentration-eect curves were quite variable, PGE 2 either had no eect, or induced contraction or relaxation of human pulmonary venous preparations ( Figure 5 ). These contractions induced by PGE 2 were inhibited by AH6809 (10 mM, n=3; data not shown).
In human pulmonary veins pre-treated with BAY u3405 (1 mM), the concentration-eect curves produced with PGF 2a were small while¯uprostenol failed to contract these tissues ( Table 1 ). The PGF 2a induced curves were abolished in the presence of BAY u3405 (1 mM) and AH6809 (10 mM; Table 1 ).
Discussion
The present report suggests the involvement of TP-and EP 1receptors in the prostanoid induced contraction of human pulmonary venous preparations.
The contractions observed with U46619 (stable thromboxane A 2 mimetic) and their inhibition by the selective TPantagonists (GR32191B, Lumley et al., 1989 and BAY u3405, McKenni et al., 1991) suggest the presence of a TP-receptor in human pulmonary veins. These results have not previously been reported although the TP-receptor has been frequently described in human pulmonary arteries (Maddox et al., 1985; Sjoberg & Steen, 1989; Lumley et al., 1989; Norel et al., 1991; Ellis & Muller-Schweinitzer, 1991; Qian et al., 1994; Jino et al., 1996) . Pharmacological studies as well as investigations using molecular biology have suggested heterogeneity among thromboxane receptors (Lumley et al., 1989; Tymkewycz et al., 1991; Furci et al., 1991; Pierce & Regan, 1998) . Actually, the anity values calculated in human pulmonary veins for GR32191B (8.25+0.34) and BAY u3405 (8.94+0.23) are comparable to those found in human pulmonary arteries: GR32191B (8.18 ± 8.3; Lumley et al., 1989; Qian et al., 1994) and BAY u3405 (9.25; Norel et al., 1991) , respectively. These data suggest that the TP-receptor present in both human pulmonary arteries and veins may be the same. In addition, the apparent pK B values obtained with GR32191B (present study) were also in accordance with those derived from pharmacological studies performed on human umbilical artery (8.04; Templeton et al., 1991), uterine artery (8.5; Baxter et al., 1995) or human platelet (8.2 ± 8.8; Lumley et al., 1989) .
The TP-receptor in human pulmonary veins was also activated by the high concentration (41 mM) of sulprostone and the TP antagonists eliminated this response. Sulprostone is classically described as a selective agonist for EP 1 -and EP 3 -receptors (Coleman et al., 1987a, b; Reeves et al., 1988) , however high concentrations (30 mM) have been reported to induce contractions of the human bronchial preparations and isolated uterine artery where TP-receptors are the only excitatory prostanoid-receptors (Coleman & Sheldrick, 1989; Baxter et al., 1995) . The ®ndings (present study) are in agreement with this previous observation, high concentrations of sulprostone may act on the TP-receptor and for this reason all the experiments involving this compound were carried out in the presence of BAY u3405.
In human pulmonary veins, sulprostone and 17-phenyl-PGE 2 (in presence of BAY u3405) induced smaller contractions than the response induced by U46619. The contractions of human pulmonary veins induced by sulprostone or 17phenyl-PGE 2 , suggest the involvement of EP 1 -or EP 3receptors. The sensitivities (pEC 50 value) of the venous preparations to sulprostone and 17-phenyl-PGE 2 were comparable to those determined in standard functional assays for EP 1 -receptor, namely, the contractions of guineapig fundus (Coleman et al., 1987a) and trachea (Lawrence et al., 1992) . In the present study, the potency ranking for these agonist, 17-phenyl-PGE 2 4sulprostone (equi-eective molar ratio=8 and 1, respectively), was similar to the one observed in the previous standard EP 1 -tissues. In these later tissues or in binding studies with cloned EP 1 -receptor (rat, Boie et al., 1997; mouse, Watabe et al., 1993; mouse, Kiriyama et al., 1997) , 17-phenyl-PGE 2 was 1.5 ± 4 fold more potent than sulprostone. A greater potency, 10 fold, was found for 17phenyl-PGE 2 when compared with sulprostone to increase intracellular Ca 2+ in rabbit cortical collecting duct via the activation of EP 1 -receptor (Guan et al., 1998) . In contrast, the rank order of potency for these agonists was reversed in studies where the eects were mediated by the activation of EP 3 -receptors. Sulprostone was a more potent contractile agonist, 30 ± 45 fold greater than 17-phenyl-PGE 2 either in human pulmonary artery (Qian et al., 1994) or when inhibiting the twitch contraction of guinea-pig vas deferens (Lawrence et al., 1992) . These results (present study) support the presence of an EP 1 -receptor associated with contraction in human pulmonary veins rather than an EP 3 -receptor. In addition, iloprost, a selective agonist for IP and EP 1receptors (SchroÈ r et al., 1981; Dong & Jones, 1982; Dong et al., 1986) induced contraction of these preparations even though IP-receptors responsible for relaxation are present (Walch et al., 1999) .
The eects of either the DP-/EP 1 -/EP 2 -receptor antagonist (AH6809; Keery & Lumley, 1988; Woodward et al., 1995) or the EP 1 -receptor antagonist (SC19220; Sanner, 1969; Kennedy et al., 1982; Coleman et al., 1987a, b) against the concentration-eect curves (present study) produced by both sulprostone and 17-phenyl-PGE 2 also suggest the involvement of the EP 1 -receptor rather than EP 3 . However, the anity values calculated or estimated for AH6809 in preparations derived from human lung (apparent pK B of 5.52 and 45.88) are lower than those obtained in similar physiological experiments performed in guinea-pig or dog EP 1 -preparations. Lawrence et al. (1992) using sulprostone or 17-phenyl-PGE 2 as the contractile agonist, found the AH6809 anity values ranking from 6.1 ± 7.35 in either guinea-pig ileum or trachea. In other studies using PGE 2 with the EP 1 -preparations (guinea-pig fundus, ileum and dog fundus), the anity values for AH6809 ranked from 6.6 ± 7.4 (Eglen & Whiting 1988; . Similarly, the estimated anity value found for SC19220 in the present study (apparent pK B 44.75) was lower than the pA 2 of 5.6 calculated in experiments performed with the previous EP 1preparations Coleman & Kennedy, 1985) . The reason for this discrepancy remains to be established. However, when EP 1 -receptors were assessed in either physiological or binding studies, the anity values for AH6809 were always one order of magnitude greater than those for SC19220 (present study; Boie et al., 1997; Funk et al., 1993) . Since high concentrations of AH6809 (5 ± 100 mM) or SC19220 (100 ± 300 mM) did not block the EP 3 mediated eects in many of the EP 3 biological models (Table 2) , the inhibitory eect of these antagonists in human pulmonary vein would suggest that the EP 3 -receptor is not involved in contractions.
The variable eects induced by PGE 2 in the human pulmonary venous preparations in presence of the TPantagonist may be explained by two opposing eects of this prostaglandin in these preparations. A contraction via the EP 1 -receptor and a relaxation via another EP-receptor subtype as has been suggested by Walch et al. (1999) . A similar paradoxical eect was observed in guinea-pig trachea as well as in human bronchial preparations where PGE 2 may act on EP 1 -and/or TP-receptors to induce contraction while the activation of the EP 2 -receptor provokes the relaxation (Gardiner, 1975; Coleman & Kennedy, 1980; McKenni et al., 1988) .
The results obtained in this report with the EP-agonists or antagonists suggest a role for EP 1 -and not EP 3 -receptor in the contraction of human pulmonary vein. The involvement of EP 1 -or EP 3 -receptors in the control of vascular tone has been principally investigated in the ocular vascular bed. The EP-agonists decrease the intraocular pressure in various animal models of glaucoma (Woodward et al., 1993; Bhattacherjee et al., 1999; Waterbury et al., 1990) and contract the pig retinal vessels (Abran et al., 1994) . However, the EP 3 -receptor is involved in vasoconstriction of guinea-pig aorta (Jones et al., 1998) , rat renal aerent arteriole (Tang et al., 2000) and human pulmonary artery (Qian et al., 1994) . Arner & HoÈ gestatt (1991) showed that iloprost contracted the human hand vein. One could associate this response with activation of an EP 1 -receptor. The data (present study) demonstrated a similar response to that of the hand veins whereas human arterial preparations did not exhibit a contractile response to this agonist (Arner & HoÈ gestatt, 1991; Qian et al., 1994) . Therefore, the presence of EP 1receptors may be found only in human venous preparations.
The low potency of PGF 2a or¯uprostenol, the selective agonist for FP-receptor, suggests that the FP-receptor is not involved in the contraction of human pulmonary veins. In addition, the small contractions induced by PGF 2a were inhibited by AH6809 suggesting that PGF 2a activates an EP 1rather than FP-receptor.
In summary, the ®ndings in the present study are consistent with the presence of TP-and EP 1 -receptors mediating constriction of human pulmonary veins. These ®ndings may be relevant to the pulmonary circulation. Sulprostone is used in obstetrics and gynaecology and one of the clinical side eects observed with this compound is pulmonary oedema (Stock et al., 1995; Levy et al., 1994; Puura et al., 1995) . The present study and the work of Qian et al. (1994) suggest that this side eect may involve vasospasm of the whole pulmonary vasculature. Such EPagonist may activate at the same time TP-, EP 3 -receptors in the arteries and TP-, EP 1 -receptors in the veins. Qian et al., 1994 The EP 3 -receptor was activated by either PGE 2 , enprostil, sulprostone or 17-phenyl-PGE 2 .
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